Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

• Sonia Philipose,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Viktoria Konya,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Mirjana Lazarevic,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Lisa M. Pasterk,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Gunther Marsche,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Sasa Frank,

  Affiliation Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria

  ⨯
• Bernhard A. Peskar,

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Akos Heinemann ,

  * E-mail: akos.heinemann@medunigraz.at

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯
• Rufina Schuligoi

  Affiliation Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

  ⨯